These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 36123063)

  • 1. ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis.
    Jiang J; Zhao C; Zhang F; Liu Z; Zhou K; Ren X; Wan Y
    BMJ Open; 2022 Sep; 12(9):e060782. PubMed ID: 36123063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
    Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
    Zhao M; Shao T; Shao H; Zhou C; Tang W
    BMC Cancer; 2024 Feb; 24(1):186. PubMed ID: 38331773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non-small cell cancer: A systematic review and network meta-analysis.
    Peng Y; Zhao Q; Liao Z; Ma Y; Ma D
    Cancer; 2023 Apr; 129(8):1261-1275. PubMed ID: 36748799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
    BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
    Luo X; Zhou Z; Zeng X; Peng L; Liu Q
    Front Public Health; 2022; 10():985834. PubMed ID: 36211665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer.
    Zheng B; Jiang H; Yang W; Li Y; Liang B; Zhu J; Chen N; Chen M; Zhang M
    Cancer Med; 2023 Aug; 12(15):15983-15997. PubMed ID: 37334877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-Line Lorlatinib or Crizotinib in Advanced
    Shaw AT; Bauer TM; de Marinis F; Felip E; Goto Y; Liu G; Mazieres J; Kim DW; Mok T; Polli A; Thurm H; Calella AM; Peltz G; Solomon BJ;
    N Engl J Med; 2020 Nov; 383(21):2018-2029. PubMed ID: 33207094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
    Solomon BJ; Bauer TM; Mok TSK; Liu G; Mazieres J; de Marinis F; Goto Y; Kim DW; Wu YL; Jassem J; López FL; Soo RA; Shaw AT; Polli A; Messina R; Iadeluca L; Toffalorio F; Felip E
    Lancet Respir Med; 2023 Apr; 11(4):354-366. PubMed ID: 36535300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
    Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
    J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.
    Fan J; Fong T; Xia Z; Zhang J; Luo P
    Cancer Med; 2018 Oct; 7(10):4993-5005. PubMed ID: 30230699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
    Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT
    Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden.
    Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C
    Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
    Elliott J; Bai Z; Hsieh SC; Kelly SE; Chen L; Skidmore B; Yousef S; Zheng C; Stewart DJ; Wells GA
    PLoS One; 2020; 15(2):e0229179. PubMed ID: 32074131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis.
    Tao Y; Zhou Y; Tang L; Chen H; Feng Y; Shi Y
    Invest New Drugs; 2022 Aug; 40(4):831-840. PubMed ID: 35435628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis.
    Luo Y; Zhang Z; Guo X; Tang X; Li S; Gong G; Gao S; Zhang Y; Lin S
    Lung Cancer; 2023 Oct; 184():107319. PubMed ID: 37597303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian perspectives: update on inhibition of
    Melosky B; Cheema P; Agulnik J; Albadine R; Bebb DG; Blais N; Burkes R; Butts C; Card PB; Chan AMY; Hirsh V; Ionescu DN; Juergens R; Morzycki W; Poonja Z; Sangha R; Tehfe M; Tsao MS; Vincent M; Xu Z; Liu G
    Curr Oncol; 2018 Oct; 25(5):317-328. PubMed ID: 30464681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.
    Yang YL; Xiang ZJ; Yang JH; Wang WJ; Xiang RL
    Ann Palliat Med; 2020 Jul; 9(4):1782-1796. PubMed ID: 32527124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
    Mok T; Camidge DR; Gadgeel SM; Rosell R; Dziadziuszko R; Kim DW; Pérol M; Ou SI; Ahn JS; Shaw AT; Bordogna W; Smoljanović V; Hilton M; Ruf T; Noé J; Peters S
    Ann Oncol; 2020 Aug; 31(8):1056-1064. PubMed ID: 32418886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
    Baldacci S; Besse B; Avrillon V; Mennecier B; Mazieres J; Dubray-Longeras P; Cortot AB; Descourt R; Doubre H; Quantin X; Duruisseaux M; Monnet I; Moro-Sibilot D; Cadranel J; Clément-Duchêne C; Cousin S; Ricordel C; Merle P; Otto J; Schneider S; Langlais A; Morin F; Westeel V; Girard N
    Eur J Cancer; 2022 May; 166():51-59. PubMed ID: 35278825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.